Explore active and passive temperature-controlled shipping solutions and their impact on clinical trial supply, balancing cost, risk, and product integrity.
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics
CDMOs must innovate production architectures to meet the demands of advanced therapeutics to ensure a reliable supply and compliance. Discover how these approaches advance modern medicine and improve patient outcomes.
-
Human Platelet Lysate (hPL) Improves Expansion Of MSCs
Learn how human platelet lysate significantly improves mesenchymal stromal/stem cell expansion and eliminates the need for plate coating, boosting yield without altering cell phenotype.
-
Immunophenotyping Of Normal Whole Blood Using A 12-Color BD Horizon™ Chroma Research Panel On The BD FACSDuet™ Premium Sample Preparation System Integrated With The BD FACSLyric™ Flow Cytometer
In this study, a fully automated workflow utilizing the BD FACSDuet™ Premium Sample Preparation System integrated with the BD FACSLyric™ Flow Cytometer was assessed and compared to manual processing.
-
Considerations For Developing The Recirculation/Perfusion Process
Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.
-
CAR Expression Detection Using Fluorescent Labeled Proteins, Flow Cytometry
Learn how site-specific fluorescent labeling addresses key challenges in flow cytometry-based evaluations by enhancing assay sensitivity, reducing variability, and ensuring reliable results.
-
Exploring Neuroinflammation, Neurodegeneration With A Brain Organ-Chip
Examine how Organ-on-a-Chip technology, accurately mimicking human neuroinflammation, offers promising human-relevant avenues for neurodegenerative disease research and therapeutic development.
-
Expert Insights In Navigating CGT's Complex Supply Chain
Examine insights shared during Cencora's ThinkLive Cell and Gene Therapy Summit 2024 that shed light on the challenges and opportunities in navigating the complexities of the cell and gene supply chain.
-
Modeling Inflammation-Specific Immune Cell Recruitment
Traditional models for studying inflammatory bowel disease (IBD) often fall short. See how the Colon Intestine-Chip was used to model the progression of IBD driven by immune cells more completely.
-
Accelerating Manufacturing Digitalization With Low-Code Development
Learn how a low-code approach to MES systems delivers speed, flexibility, and compliance, empowering manufacturers to overcome bottlenecks and embrace digital transformation with confidence.
-
Performance Of HEKima™ Adherent HEK Cell Medium
Explore the performance of a serum-free medium designed for HEK-293 cells, comparing its efficacy to traditional media for protein expression and cell proliferation.
NEWSLETTER ARCHIVE
- 02.14.26 -- Cell & Gene Best Of January
- 02.13.26 -- Strengthening Your Regulatory Path: Strategies For Compliance And Safety
- 02.13.26 -- Developing Itvisma For Broad-Range Treatment Of SMA With Dr. Norman Putzki
- 02.12.26 -- Why Your MVP And Its Evolution Matters To Manufacturing
- 02.11.26 -- Breakthroughs In Cell Research & Automation
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections